Significant efficacy in the treatment of HBV infected with nucleoside drugs in noofovir

TDF is a ringless nucleotide reverse transcriptase inhibitor approved by the FDA for the treatment of human immunodeficiency virus (HIV) infectionThe drug showed activity against HBV (including wild HBV and ramifdin resistant HBV) when used in the treatment of HIV-combined hepatitis B virus (HBV) infection patientsB?included 121 cases of chronic HBV infection (HBV DNA s 105 copies/ml) from 13 medical centers in Germany and the Netherlands, with 87 cases ofmen, with an average age of (45 to 12) and 70 cases of HBeAg positivePrior to TDF treatment, 105 patients were treated with ramifedinandin and 75 were treated with ADV due to Ramirez resistanceFourteen patients were genotype ADV drug resistant, 6 were withdrawn due to TDF intolerance, and a total of 101 patients received TDF treatment, with an average of 14.8 to 12 monthsThe results showed that HBV DNA decreased from the average baseline level of (6.7 to 1.3) log copies/ml) to log copies/ml at 24 weeks (3.8 x 1.1) log copies/ml and 48 weeks (4.1?1.2) log copies/mlAt 24 and 48 weeks, 72% and 91% of patients who were negative for HBV DNA (400 copies/ml), respectivelyThe study also did not suggest that TDF resistance was not observed in patients with relapseAfter an average of 23% of patients with HBeAg serum conversion after an average of TDF treatment (9 to 3)At the time of treatment (13 to 6) months, 4% of patients had a decrease in HBsAgIn 85 patients (70%) the level of alanine amino metastase (ALT) increased at baseline, and after 48 weeks of TDF treatment, 78% of patients returned to normal ALT levelsThere were noof significant adversereactions during treatment